schizophrenia Archives - Amazing Health Advances

Marijuana and Schizophrenia?

The AHA! Team — Fri, 31 May 2024 05:31:56 +0000

Michael Greger M.D. FACLM via Nutrition Facts – The evidence linking cannabis use to psychotic disorders is considered strong enough to warrant a public health warning. “Even as proponents of [cannabis] legalization contend that smoked marijuana is a harmless natural substance that improves the quality of life, a growing body of evidence links it in a small but significant number of users to…the induction or aggravation of psychosis.” “Psychotic disorders are arguably the most serious of mental illnesses, the best known being schizophrenia.” “Schizophrenia, an illness that is characterized by delusions, hallucinations, and odd behavior, is among the top 10 leading causes of disability in the United States. It affects approximately 1% of the general population.” Can cannabis cause it? Schizophrenia… affects approximately 1% of the general population As I discuss in my video Does Marijuana Cause Schizophrenia?, over the last half-century, “nearly 2,000 studies have been published on this topic…and the pro-psychotic effects of cannabis have dominated media reporting about this drug. But how clear is the link?” Population studies have “consistently demonstrated a strong, positive, and dose-dependent association between cannabis use and the risk of psychotic disorders.” Indeed, studies have shown that the more cannabis people use, the more likely they are to be psychotic, as seen in a chart below and at 1:10 in my video. However, that doesn’t mean cannabis is the cause. It could just be a correlation or even a consequence of the disease. “The link between cannabis and psychosis is well established,” but it may be the case that patients with mental health problems self-medicate and “use cannabis to relieve their distress.” The link between cannabis and psychosis is well established… As you can see below and at 1:38 in my video, there isn’t only a link between cannabis and psychosis in snapshot-in-time cross-sectional studies, but in cohort studies as well, where people are followed over time. Research has shown that cannabis use often precedes psychosis, not the other way around. Now, it goes without saying that “the vast majority of people who use cannabis do not develop psychotic disorders such as schizophrenia, and many people diagnosed with such disorders have never used cannabis.” But, overall, these studies are considered to be “strong enough evidence to warrant a public health message that cannabis use can increase the risk of psychotic disorders.” There is another potential explanation: Even though cannabis use precedes schizophrenia, could it be that whichever genes drive schizophrenia also make it more likely you start smoking pot? The biggest strike against the cannabis-schizophrenia link is country-by-country ecological studies that don’t seem to show more disease in areas where there’s more use. And, overall, schizophrenia rates seem to have remained stable or even gone down worldwide since the 1960s, even though there’s been a big bump in cannabis use since then. If about 10 percent of schizophrenia cases are attributable to marijuana use and there’s been a fourfold increase in use, why hasn’t there been a 40 percent increase in the prevalence of schizophrenia? The problem with that argument is “there is little reliable evidence on the temporal [true] trends in the incidence of schizophrenia, so it is difficult to know whether this statement is true or not.” Perhaps it’s more of an issue with potency rather than just cannabis in general. Indeed, “the incidence of schizophrenia is higher in countries…where high-potency cannabis has taken over the market compared with countries…where more traditional forms of cannabis are smoked.” The bottom line is you don’t know until you put it to the test. You can’t just randomize kids to cannabis, but, in a way, Nature set up a natural experiment for us. There are genes that kids randomly get that can increase their likelihood of smoking pot. Do those kids then go on to have a higher risk of schizophrenia? Yes, research “findings strongly support” all of those population studies that suggest “cannabis plays a causal [cause-and-effect] role in the development of schizophrenia.” Okay, but by how much? Let’s break it down. Even if cannabis use doubles the risk, that would mean only going from a 7-in-1,000 chance of developing a psychosis to 14 in 1,000. So, going from a 1 in 140 chance to a 1 in 70 chance. It would be different if schizophrenia runs in your family, where a doubling of risk could mean going from a one-in-ten chance to one in five, but, on a population scale, it could take thousands of cannabis users quitting to prevent a single case of schizophrenia. So, from a public health standpoint, “addiction is a far more common problem.” Researchers “estimate that people who try cannabis are ninefold more likely to become addicted to it”—even though that itself is relatively rare—“than to develop psychosis in their lifetime.” I have an entire series of videos on cannabis, which I originally released in a webinar and downloadable digital DVD. Key Takeaways Although some proponents of cannabis legalization argue that marijuana is a “harmless natural substance that improves the quality of life,” it has been linked “in a small but significant number of users to…the induction or aggravation of psychosis.” Schizophrenia, a psychotic disorder characterized by hallucinations, odd behavior, and delusions, affects about 1 percent of the general population. Studies have found that the more cannabis people use, the more likely they are to be psychotic, but that could just be a correlation or even a consequence of the disease. Individuals with mental health problems may self-medicate and use cannabis to relieve distress, for example. Research has found that cannabis use often precedes psychosis, not the other way around. Overall, there appears to be “strong enough evidence to warrant a public health message that cannabis use can increase the risk of psychotic disorders.” There does not seem to be more disease in regions with greater cannabis use. Overall, schizophrenia rates appear to have remained stable or even declined worldwide since the 1960s, despite a large jump in cannabis use since then. Potency may be a bigger issue. In countries with higher potency cannabis, the incidence of schizophrenia is higher than in countries with “more traditional forms.” Some genes can increase our likelihood of using cannabis, and kids who randomly get them have been found to have a higher risk of schizophrenia. Research suggests that cannabis may have a cause-and-effect role in the development of that psychosis. Even if cannabis use doubles the risk, however, that would just mean a 1-in-70 chance of developing a psychosis without a family history of schizophrenia. From a public health standard, the far more common problem is addiction. To read the original article click here.

The post Marijuana and Schizophrenia? appeared first on Amazing Health Advances.

High-Strength Cannabis Linked to Addiction and Mental Health Problems

AHA Publisher — Wed, 27 Jul 2022 07:00:57 +0000

University of Bath via Newswise – As the strength or potency of cannabis products has increased internationally over the years, so have rates of people being treated for cannabis addiction, say the authors of a new study. Researchers from the Addiction and Mental Health Group at the University of Bath (UK) systematically analysed the relationship between the types of cannabis people use and their addiction and mental health problems. Their work draws on 20 studies involving almost 120,000 people. After alcohol and nicotine, cannabis is the most widely used drug globally. Latest estimates from the UK suggest that over the last year around one in five 16-24 year olds had used cannabis. Cannabis potency refers to the concentration of tetrahydrocannabinol (THC) in cannabis – the key psychoactive drug it contains. Recent studies from the same team at Bath have found that the concentration of THC in cannabis has increased significantly over time meaning that cannabis used today is typically much stronger than previously. The new study, published in The Lancet Psychiatry, suggests that people who use high potency cannabis are more likely to experience addiction than those using low potency products. It also suggests that people using high potency cannabis are more likely to experience a psychotic disorder, such as schizophrenia. These findings may help to explain why more people have received treatment for cannabis problems over recent years. Data from the European Monitoring Centre for Drugs and Drug Addiction show a 76% increase in people entering treatment for cannabis addiction in the past decade. Based on these new results, the authors argue that public health guidelines and policies to help make cannabis use safer should be encouraged. Lead author, Kat Petrilli from the University of Bath’s Department of Psychology explained: “Our systematic review found that people who use higher potency cannabis could be at increased risks of addiction as well as psychosis when compared to people who use cannabis products with lower potencies. “These results are important in the context of harm reduction which aims to minimise the negative consequences associated with drug use. While the safest level of use for cannabis is of course ‘no use’, it is important to acknowledge that a significant number of people across the world use cannabis regularly and to ensure they can make informed decisions that could reduce any possible harms associated with it.” The authors point out that strategies to make cannabis use safer could inform how the drug is regulated in the UK and internationally. Recreational cannabis use remains illegal in the UK, but cannabis products are now legally sold for recreational use in Canada, Uruguay, and parts of the USA. Several other countries appear set to follow this trend, including Germany. In the UK, the Liberal Democrats have argued that a legal regulated market could make cannabis use safer by enforcing a limit on the potency of cannabis products, and investing the revenue and savings from this into education and treatment for cannabis problems. Senior author, Dr Tom Freeman explained: “Our findings suggest that people who use cannabis could reduce their risk of harm by using lower potency products. In places where cannabis is legally sold, providing consumers with accurate information on product content and access to lower potency products could help people to use cannabis more safely.” Despite anecdotal evidence of links between cannabis and anxiety and depression, the authors note that the links between cannabis potency and other mental health problems are unclear. This research was funded by the Economic and Social Research Council. To read the original article click here.

The post High-Strength Cannabis Linked to Addiction and Mental Health Problems appeared first on Amazing Health Advances.

What is Nutritional Psychiatry?

AHA Publisher — Fri, 04 Feb 2022 08:00:05 +0000

Joelle Hanson-Baiden, BSc via News-Medical – Nutritional psychiatry is the practice of using food and food supplements as alternative treatments for mental health disorders. Most current treatments for mental health disorders – from psychotic disorders such as schizophrenia to neurodegenerative diseases such as dementia – focus on treating the symptoms of the condition. Though many are effective at treating these symptoms, they are often paired with severe side effects. Over recent years, there has been a considerable increase in research surrounding links between psychiatric disorders and diet. As such, there has been an increase in research surrounding nutritional-based treatments for these disorders. From these studies, different treatment targets have been identified, including the gut biome and nutrient deficiencies. Current research is promising and provides insight into alternative interventions for treating psychiatric disorders. Potential Pathways that Link Diet and Psychiatric Disorders Diet might be associated with severe mental health disorders such as schizophrenia-spectrum disorders, psychosis, and dementia. There are several potential pathways research has found to be involved, such as the gut biome and nutrient deficiencies. The Gut Biome Research suggests that there is a link between the gut biome and the development of psychiatric disorders such as depression and schizophrenia. The gut biome consists of bacteria, fungi, and viruses found in the gastrointestinal tract. Studies have shown that individuals with schizophrenia and psychosis present with different gut microbial compositions compared to non-psychiatric individuals. In a study comparing the gut microbial composition of individuals with first-episode psychosis (FEP) and non-FEP individuals, researchers found that the composition of the gut in: “Numbers of Lactobacillus group bacteria were elevated in FEP-patients and significantly correlated with severity along different symptom domains.” (Schwarz et al., 2018). These results suggest that alterations in the microbial composition of the gut can increase one’s risk of developing a psychiatric disorder. Research suggests that the microbiota-gut-brain axis (MGBA) underlies this risk. The MGBA connects the intestines with the central nervous system and studies have shown that individuals with schizophrenia can present with disruptions of the MGBA. “Several interactions between the gut and the brain have been observed, including vagal nerve activation, immune system modification, the synthesis of neurotransmitters and alterations of neurotransmitter pathways.” (Teasdale et al., 2020) Nutrient Deficiencies Nutrient deficiencies are caused by insufficient intake of said nutrients or poor absorption by the body. Research shows that nutrient deficiencies are one of the risk factors for developing mental disorders. Example deficiencies include vitamin B9 (folate) B6 and B12 deficiencies. These B vitamins are essential for DNA and protein synthesis. Both of which play a key role in brain development and cognition. Several studies have shown that individuals with schizophrenia have lower serum vitamin B6 and B9 (folate) levels than non-psychiatric individuals. A deficiency in vitamin D has also been shown to be highly prevalent in people with schizophrenia and dementia. “There are stronger associations between severe vitamin D deficiency (<10 ng/ml) and both dementia and AD compared to moderate vitamin D deficiency (10-20ng/ml).” (Chai et al., 2019). Vitamin D is necessary for modulating neurotransmitter release, including dopamine – known to be imbalanced in mental disorders. Brain Food? How Nutritional Psychiatry Targets these Pathways The International Society for Nutritional Psychiatry Research (ISNPR) was formed to give guidance to clinicians and healthcare workers on offering nutritional treatments to patients with mental health issues. The ISNPR has issued many recommendations in recent years. These recommendations are heavily focused on promoting an optimal gut biome composition. The ISNPR suggests that changes in the type of food eaten can improve the composition of the gut biome. Following traditional diets such as Mediterranean, Scandinavian, or Japanese diets is recommended. These diets consist of high volumes of fresh fruit and vegetables, whole grains, and a limited intake of processed foods. The concentration of bacteria in the gut can also be altered with probiotics – live bacteria and yeasts. These can be found in fermented foods (e.g., kimchi and sauerkraut) and yogurt. Probiotics can also be taken as supplements. Alongside improving the gut biome, the ISNPR also recommends the intake of nutrient supplements. These include vitamins B9, B6, B12, and vitamin D. Research has shown that administering these vitamins is effective in shortening the duration of illness in individuals with psychosis and schizophrenia. Food for Thought: Traditional vs Nutritional Psychiatry, Which is More Effective? Nutritional psychiatry is non-invasive, has very few side effects, and is easily accessible to all. Compared to nutritional psychiatry, traditional treatments can have very severe side effects and do little for deteriorating physical health. The evidence for the effects of nutritional treatments on symptomatology is still fresh as many clinical trials are still in progress. Despite this, nutritional psychiatry allows for the physical health of people with severe mental health issues such as schizophrenia and psychosis, which have otherwise been neglected. Neglected physical health in these individuals has led to higher rates of obesity, diabetes, hypertension, and other cardiovascular diseases. In turn, this has led to a large decrease in life expectancy. This together with the symptoms of the condition, side effects from medication, and cognitive impairments causes a significant decrease in the quality of life of these individuals. Nutritional psychiatry, therefore, acts to improve the quality of life of people who suffer from mental health illnesses. Nutritional psychiatry can therefore impact the lives of these people greater than traditional psychiatry alone. Further in-depth research is needed to widen this impact. To read more about the role nutrition plays in health, click here! References: Chai, B., Gao, F., Wu, R., Dong, T., Gu, C., Lin, Q., & Zhang, Y. (2019). Vitamin D deficiency as a risk factor for dementia and Alzheimer’s disease: an updated meta-analysis. BMC Neurology, 19(1). https://doi.org/10.1186/s12883-019-1500-6 Chiang, M., Natarajan, R., & Fan, X. (2016). Vitamin D in schizophrenia: a clinical review. Evidence Based Mental Health, 19(1), 6–9. https://doi.org/10.1136/eb-2015-102117 Grosso, G. (2021). Nutritional Psychiatry: How Diet Affects Brain through Gut Microbiota. Nutrients, 13(4), 1282. https://doi.org/10.3390/nu13041282 Schwarz, E., Maukonen, J., Hyytiäinen, T., Kieseppä, T., Orešič, M., Sabunciyan, S., Mantere, O., Saarela, M., Yolken, R., & Suvisaari, J. (2018). Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response. Schizophrenia Research, 192, 398–403. https://doi.org/10.1016/j.schres.2017.04.017 Teasdale, S., Mörkl, S., & Müller-Stierlin, A. S. (2020). Nutritional psychiatry in the treatment of psychotic disorders: Current hypotheses and research challenges. Brain, Behavior, & Immunity – Health, 5, 100070. https://doi.org/10.1016/j.bbih.2020.100070 To read the original article click here.

The post What is Nutritional Psychiatry? appeared first on Amazing Health Advances.

Ten Medical and Scientific Breakthroughs of 2021 at Mount Sinai

AHA Publisher — Tue, 04 Jan 2022 08:00:25 +0000

Mount Sinai Health System via Newswise 1. Ketamine Infusions Found Promising for PTSD A team of researchers led by Dennis Charney, MD, Dean of the Icahn School of Medicine, and Adriana Feder, MD found that repeated intravenous ketamine infusions appeared efficacious in reducing symptom severity among individuals with chronic PTSD. Their study was published in The American Journal of Psychiatry. “We want people suffering with PTSD to know that hope is on the horizon, and we are working diligently to collect the information that will help bring them the relief they so desperately need,” said Dr. Feder. Speech Changes Predictor of Schizophrenia Risk Researchers hope to use speech changes to predict which adolescents and young adults are at high risk for schizophrenia and may go on to develop the disease. In a new study published in The Lancet journal E Clinical Medicine found that the artificial intelligence program predicted, with 75 percent accuracy, who would get Alzheimer’s disease. Cheryl Corcoran, MD, explains, “It’s been a lot of small studies finding the same signals.” At this point, she said, “We are not at the point yet where we can tell people if they are at risk or not.” First Successful Trachea Transplant Eric Genden, MD, and Sander Florman, MD, led a large team to perform the first successful transplant of a trachea, giving hope for patients throughout the world and future treatments of those who have been on ventilators. Dr. Genden said, “Although it seemed like a pretty straightforward thing, because at first sight it seems just like a tube, it turns out it’s a highly complex organ system. New Cancer Vaccine a Game Changer for Young and Old Patients Thomas Marron, MD, PhD, is developing a personalized cancer vaccine that was tested in a phase one trial. Dr. Marron and a lung cancer patient in the trial, a 74-year-old retired attorney, discussed the promising outcomes in a news report. “The cancer vaccines try to teach your immune system how to recognize your cancer and eliminate it,” Dr. Marron said. “Our initial data suggest that, after getting all 10 vaccines, patients can be very strongly immunized against their cancer.” Apple Watch Used to Measure Resilience in Health Care Workers A new study led by Robert Hirten, MD, and Zahi Fayad, PhD, published in the Journal of Medical Internet Research, shows how using wearable devices can track health care worker resiliency during the pandemic. Researchers from Mount Sinai gave 361 health care workers from seven hospitals across New York City Apple Watches to measure their heart rate. The study’s participants also downloaded a customized app to complete surveys each week that measured resilience, emotional support, stress, optimism and quality of life. Dr. Fayad said, “The experience of this pandemic has been especially stressful for health care workers, and as a community we need to be able to support them, especially as the virus persists. Our study is one of the first to document not only the toll the pandemic has taken on our health care workers, but also the importance of resilience and social support as specific paths toward efficiently and effectively directing support.” Launch of Department of Artificial Intelligence and Human Health Thomas Fuchs, DSc, and Dennis Charney, MD, Dean of the Icahn School of Medicine, announce the first-of-its-kind Artificial Intelligence and Human Health Department at the Mount Sinai Health System. Dr. Fuchs said, “If you are serious about this, then computer scientists have to work together with the physicians in the trenches. One reason why big tech has failed in health care is that even with all their talent, if you’re just throwing artificial intelligence over the fence into a hospital, that doesn’t work. It has to come out of systems like ours.” COVID-19 Vaccine Less Protective for Multiple Myeloma Patients A new study led by Samir Parekh, MBBS, and published in the journal Cancer Cell shows how COVID-19 vaccines may be less protective for multiple myeloma patients. “[This research] suggests that booster shots are looking extremely promising for people with multiple myeloma,” said Dr. Parekh. “Patients who haven’t received them should do that immediately.” Long COVID Has Long-Lasting Impact A study published in the American Journal of Physical and Rehabilitation Medicine and led by David Putrino, PhD, showed that the impact on everyday functioning in patients with long COVID lasted at least a year after initial infection. “Our work and the work of others has shown that this affects people’s abilities to make plans, synthesize information, and do their daily activities of work,” said Dr. Putrino. “They suffer from a lot of memory loss and inability to form new memories, as well as difficulty with speaking. This is a very debilitating condition with serious cognitive conditions.” Cannabis Use in Pregnancy Women who use cannabis during their pregnancies could be putting their children at risk of developing mental health and behavioral problems, according to a new study by Yasmin Hurd, PhD, and published by the journal Proceedings of the National Academy of Sciences. “I do think that pregnant women and their physicians need to have more discussions about cannabis use, just like they have in terms of alcohol,” said Dr. Hurd. “Then they need to be given the resources to be able to get help for themselves and their children. This is not about stigmatizing women. It’s the opposite. It’s about the more knowledge you have, the more power you have.” Lung Cancer Screening Saves Lives Early detection and the increased use of screening for lung cancer are saving lives, according to a study published on JAMA Network Open. Screening patients using CT scans and following up on potential cancers helps physicians identify precancerous and early cancer tissue growth to surgically remove, leading to a decline in lung cancer deaths, Mount Sinai Health System researchers report. Raja Flores, MD, the study’s lead author and Chair of Thoracic Surgery at the Mount Sinai Health System, said, “If we find lung cancer early, we can cure it with surgery. Early screening is the key.” To read the original article click here.

The post Ten Medical and Scientific Breakthroughs of 2021 at Mount Sinai appeared first on Amazing Health Advances.